TNGX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -33.86. Updated 2026-07-23.
Tango Therapeutics (TNGX) Research Hub
Tango Therapeutics (TNGX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 23.78 USD (-0.92%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -33.86, market cap 3.55B. This hub links to the full technical, earnings and options research available for TNGX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 23.78 USD (-0.92%) |
| 52-week range | 22.07 USD – 34.39 USD |
| Trend regime | Range |
| 14-day RSI | 34 (Bearish) |
| Trailing P/E | -33.86 |
| Market cap | 3.55B |
| Dividend yield | 0.00% |
Available research for TNGX
Covered Call on TNGX: how it works, illustrative setup around the real 23.78 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TNGX: how it works, illustrative setup around the real 23.78 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TNGX: how it works, illustrative setup around the real 23.78 USD price, max profit/loss, breakeven and when to use it. Educational.
TNGX technical analysis: range, last 23.78 USD, RSI 34, 52w range 22.07 USD–34.39 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is TNGX in?
Tango Therapeutics (TNGX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TNGX in an uptrend or downtrend?
As of 2026-09-11, TNGX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TNGX's trailing P/E ratio?
TNGX's trailing P/E is -33.86, with a market cap of 3.55B. See the earnings research page for full valuation detail.